DD

Study: Nearly 50% of subjects preferred medical marijuana over prescription drugs; FDA & DEA to Adjust Doctrines

Aurora Cannabis, Canopy Growth, and Aphria Hemp struck a big win this week as a new study has been released that shows Cannabis with THC has shown to be on the same level of effectiveness as opioid prescription drugs. Currently, the three powerhouse Cannabis companies are held back by red tape still in place by the FDA (for trademark protection and licences) and the DEA (to make a successful transition into US market). However, this study is now making the FDA and DEA adjust their industry doctrines on THC which will open the door to companies wishing to enter the US market. Effectively, this will allow the 3 marijuana giants to continue with their push into the US market.

The study, by Daniel Kruger of the UM Institute for Social Research, found that 44 percent of medical cannabis users stopped taking a pharmaceutical drug, or used less of one, or both, in favor of cannabis.

Kruger and co-author Jessica Kruger, conducted the study to assess attitudes and use of medical cannabis and the mainstream health care system—described as either a doctor or hospital—among marijuana users.

The study found that in general, people use medical marijuana to treat pain, back problems, depression and headaches. The majority of participants said their mainstream healthcare provider did not know that they used medical cannabis, indicating gaps between the two treatment systems.

Researchers surveyed 450 adults who identified as current cannabis users. The majority reported using marijuana to help treat a medical or health condition. Users rated marijuana better than pharmaceutical drugs on effectiveness, side effects availability and cost.

“This study advances knowledge in the evidence-based approach to harm reduction and benefit promotion regarding medical cannabis,” said Daniel Kruger, a member of the U-M Institute for Healthcare Policy and Innovation. “Given the growing use of cannabis for medical purposes and the widespread use for recreation purposes despite criminalization, the current public health framework focusing primarily on cannabis abstinence appears obsolete.”

This comes after a recent study out of the Netherlands found that,

standardised pharmaceutical-grade cannabis with a high tetrahydrocannabinol (THC) content was effective in treating the musculoskeletal pain caused by fibromyalgia.

Conducted by Leiden University Medical Centre (LUMC) in co-operation with Bedrocan International, the study involving the pharmaceutical-grade cannabis provided by the company further found “cannabis flos with only cannabidiol (CBD) did not provide the patients with relief.”

From this, many analysts are suggesting that the marijuana and hemp powerhouses are posturing to trademark their CBD products now that Donald Trump has signed the bill. One emerging Cannabis company has possibly found a way past this. Profile Solutions Inc (PSIQ)instead has purchased one of the most well known brands in the Cannabis industry, that of Cheech & Chong Product Line. While these are currently only mens grooming products, they are already trade marked. Now, when their large scale growing operation goes operational (See Here), they will only have to put the CBD products under the banner of Cheech and Chong, and thus it would be trade marked.

Aphria announced Wednesday it has struck a deal with Insumos Medicos to provide the Paraguayan pharmaceutical company with medical-grade cannabis, the first such deal in the country. Paraguay will become Aphria’s third market in Latin America, following Argentina and Colombia, which follows PSIQ’s expansion into Latin America.

Leave a Reply

Your email address will not be published. Required fields are marked *